Glenn Sblendorio has served as a member of the 4DMT board of directors since January 2026 (appointed as a Class I director effective January 5, 2026, and to the Compensation Committee and Science and Technology Committee).
Mr. Sblendorio most recently was Chief Executive Officer and a member of the board of directors of IVERIC bio, Inc. from July 2017 to its acquisition by Astellas Pharma, Inc. in July 2023. Prior to IVERIC, he was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and a member of its board from July 2011 through December 31, 2015. Before that, he was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From 1998 through 2000, he served as a Managing Director of MPM Capital Advisors.
Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University, and is a graduate of the Harvard Advanced Management Program.